MedTrace Logo

Whole-body Hyperthermia for Mild to Moderate Depressive Disorder

NCT03906175 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2023-12-04

No results posted yet for this study

Summary

The primary aim of this study is to investigate the effectiveness of whole-body hyperthermia in comparison to wait list on depressive symptom severity in patients with mild to moderate depressive disorder currently not under psychotherapeutic or antidepressant drug treatment.

Secondary aims included further quality of life outcomes, immunological parameters, and tolerability/safety of the hyperthermia.

Conditions

  • Depression, Unipolar

Interventions

DEVICE

Whole-body hyperthermia

Whole-body hyperthermia will be applied two times during 4 weeks (week 0 and 2 after randomization). The hyperthermia will be applied using Heckel-HT3000 MPIIb.

Sponsors & Collaborators

  • Universität Duisburg-Essen

    lead OTHER

Principal Investigators

  • Gustav Dobos, Prof. MD · Center for Integrative Medicine and Health, University Hospital Essen, University of Duisburg-Essen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-11
Primary Completion
2023-08-31
Completion
2023-09-01

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03906175 on ClinicalTrials.gov